Presentation Date / Time Title Lead Author Abstract # (CDT) Location Erbitux (cetuximab) Poster Sessions Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the Timothy Jay Sun, Jun 03, phase 2 APEC Price, MBBS, 8:00 AM - 11:30 trial. FRACP, D.H.Sc 3534 AM Hall A Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 plus or minus cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the Sun, Jun 03, phase 3 TAILOR Shukui Qin, 8:00 AM - 11:30 trial. MD, BA 3521 AM Hall A Publication Cost-effectiveness (CE) of FOLFIRI (F) + cetuximab vs F + bevacizumab in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Stintzing S, data from the van Oostrum FIRE-3 (AIO I, Pescott KRK-0306) study CP, et al. e15711
Presentation Date / Time Title Lead Author Abstract # (CDT) Location Avelumab Oral Presentations Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma Mon, Jun 04, progressed on Paul Nghiem, 10:12 AM - Arie Crown chemotherapy. MD, PhD 9507 10:24 AM Theater Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results Fri, Jun 01, from JAVELIN Lung Alice Tsang 4:30 PM - 4:42 101. Shaw, MD, PhD 9008 PM Hall D1 Poster Sessions Avelumab (anti-PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up Sun, Jun 03, from the JAVELIN Arun Rajan, 8:00 AM - 11:30 Solid Tumor trial. MD 9090 AM Hall A Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from Sun, Jun 03, JAVELIN Solid Raffit 8:00 AM - 11:30 Tumor. Hassan, MD 8563 AM Hall A Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded John WT Mon, Jun 04, access program Walker, MD, 1:15 PM - 4:45 (EAP). PhD 9537 PM Hall A Association of efficacy and adverse events of Karen Kelly, special interest MD, FASCO of avelumab in the JAVELIN solid Mon, Jun 04, tumor and JAVELIN 8:00 AM - 11:30 Merkel 200 trials. 3057 AM Hall A SPEAR-bladder (study informing treatment pathway decision in bladder cancer): First- through third-line time to Sat, Jun 02, treatment failure Gurjyot K. 8:00 AM - 11:30 in the US. Doshi, MD 4544 AM Hall A Publication Avelumab in patients with previously treated metastatic melanoma: phase 1b Keilholz U, results from the Mehnert J, JAVELIN Solid Bauer S, et Tumor trial al. e21531 Characteristics, treatment patterns and safety events from 4 cohorts of advanced or metastatic cancer Russo L, patients based on Esposito D, healthcare claims Lamy FX, et data al. e13603 Healthcare resource use and expenditures among patients with Kearney M, Merkel cell Thokagevistk carcinoma by level K, Boutmy E, of comorbidity et al. e18932 Projecting long-term survival for avelumab in Phatak H, patients with Proskorovsky refractory Merkel I, Lanitis T, cell carcinoma et al. e21623 Predicting overall survival in patients (Pts) with treatment-naive metastatic Merkel Bullement A, Cell carcinoma D'Angelo SP, (mMCC) treated Amin A, et with avelumab al. e21620 A novel, open-access data commons for improved disease Murphy M, management in Sartor O, Merkel cell Bertagnolli carcinoma patients M, et al. e21544
Presentation Date / Time Title Lead Author Abstract # (CDT) Location M7824 (beta-trap) Oral Presentation Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-beta, in patients with HPV Sat, Jun 02, associated Julius 5:12 PM - 5:24 cancers. Strauss, MD 3007 PM Hall B1 Poster Discussion Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein Luis G. Sun, Jun 03, targeting TGF-beta Paz-Ares, MD, 11:30 AM - Arie Crown and PD-L1. PhD 9017 12:45 PM Theater Poster Session Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein Yulia Mon, Jun 04, targeting TGF-beta Vugmeyster, 8:00 AM - 11:30 and PD-L1. PhD 2566 AM Hall A
Presentation Date / Time Title Lead Author Abstract # (CDT) Location Tepotinib Poster Discussion Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping Sun, Jun 03, mutations: Phase Enriqueta 11:30 AM - Arie Crown II trial. Felip, MD 9016 12:45 PM Theatre Poster Session Can duration of response be used as a surrogate endpoint for overall survival in advanced Sun, Jun 03, non-small cell Boris M 8:00 AM - 11:30 lung cancer? Pfeiffer 9082 AM Hall A
(CONTINUA)
